143 related articles for article (PubMed ID: 35497888)
21. [Sirolimus-induced lymphedema in a kidney-transplant recipient: Partial recovery after changeover to tacrolimus].
Al Gain M; Crickx B; Bejar C; Chen L; Azeroual L; Marinho E; Descamps V
Ann Dermatol Venereol; 2015 May; 142(5):350-5. PubMed ID: 25683011
[TBL] [Abstract][Full Text] [Related]
22. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
23. The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation.
Lichtenberg S; Rahamimov R; Green H; Fox BD; Mor E; Gafter U; Chagnac A; Rozen-Zvi B
Eur J Clin Pharmacol; 2017 Jul; 73(7):819-826. PubMed ID: 28342067
[TBL] [Abstract][Full Text] [Related]
24. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
[TBL] [Abstract][Full Text] [Related]
25. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
26. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
27. The effect of transfer to adult transplant care on kidney function and immunosuppressant drug level variability in pediatric kidney transplant recipients.
Fernandez HE; Amaral S; Shaw PA; Doyle AM; Bloom RD; Palmer JA; Baluarte HJ; Furth SL
Pediatr Transplant; 2019 Sep; 23(6):e13527. PubMed ID: 31209988
[TBL] [Abstract][Full Text] [Related]
28. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
[TBL] [Abstract][Full Text] [Related]
29. Anorexia nervosa in a pediatric renal transplant recipient and its reversal with cyclosporine.
Okechuku G; Boulos AK; Herman L; Upadhyay K
Pediatr Transplant; 2015 May; 19(3):E78-82. PubMed ID: 25661468
[TBL] [Abstract][Full Text] [Related]
30. Preventive Role of mTOR Inhibitor in Post-Kidney Transplant Urothelial Carcinoma.
Chang YL; Lee HC; Luo HL; Chen YT; Chiang PH; Cheng YT
Transplant Proc; 2019 Oct; 51(8):2731-2734. PubMed ID: 31447189
[TBL] [Abstract][Full Text] [Related]
31. Blood pressure control in kidney transplant recipients: influence of immunosuppression.
Gerhardt U; Riedasch M; Hohage H
J Auton Pharmacol; 1999 Feb; 19(1):49-54. PubMed ID: 10385269
[TBL] [Abstract][Full Text] [Related]
32. Sensorineural Deafness Following Tacrolimus Use.
Lakshmi BS; Vidya B; Reddy MHK; Kumar ACV; Ram R; Kumar VS
Exp Clin Transplant; 2020 Feb; 18(1):110-111. PubMed ID: 29969081
[TBL] [Abstract][Full Text] [Related]
33. Problems with paper entitled The impact of tacrolimus exposure on extrarenal adverse effects in adult transplant recipients.
Jones TE
Br J Clin Pharmacol; 2020 Dec; 86(12):2536-2537. PubMed ID: 31849089
[No Abstract] [Full Text] [Related]
34. Immunosuppression, BK polyomavirus infections, and BK polyomavirus-specific T cells after pediatric kidney transplantation.
Ahlenstiel-Grunow T; Pape L
Pediatr Nephrol; 2020 Apr; 35(4):625-631. PubMed ID: 31858227
[TBL] [Abstract][Full Text] [Related]
35. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
Noble J; Jouve T; Rostaing L; Malvezzi P
Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
[TBL] [Abstract][Full Text] [Related]
36. Cochlear sensitivity in children with chronic kidney disease and end-stage renal disease undergoing hemodialysis.
Renda R; Renda L; Selçuk ÖT; Eyigör H; Yılmaz MD; Osma Ü
Int J Pediatr Otorhinolaryngol; 2015 Dec; 79(12):2378-83. PubMed ID: 26590002
[TBL] [Abstract][Full Text] [Related]
37. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.
Cheng F; Li Q; Wang J; Zeng F; Zhang Y
J Clin Pharm Ther; 2021 Dec; 46(6):1636-1649. PubMed ID: 34342024
[TBL] [Abstract][Full Text] [Related]
38. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
39. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.
Rojas L; Neumann I; Herrero MJ; Bosó V; Reig J; Poveda JL; Megías J; Bea S; Aliño SF
Pharmacogenomics J; 2015 Feb; 15(1):38-48. PubMed ID: 25201288
[TBL] [Abstract][Full Text] [Related]
40. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
